Big Pharma's Immunology Spring Cleaning Has Begun

That competitive pressure creates a vicious cycle. Companies need to invest heavily in immunology because the market is enormous. But the existing drugs are so effective that newcomers have to be significantly better, not just "pretty good." The result: a lot of expensive programs that look promising in early testing but can't survive contact with the real world.

In immunology, the odds of making it to market feel especially steep because the competition at the finish line is so fierce.

Neither Company Is Running Away

What makes these cuts interesting (rather than alarming) is that both Boehringer and Amgen are doubling down on immunology everywhere else. They're not retreating. They're pruning.

Think of it like a gardener cutting dead branches so the healthy ones get more sunlight. Boehringer Ingelheim has been on an immunology shopping spree. In February 2026, the company signed a deal worth up to $500 million with Sitryx Therapeutics to license preclinical oral small molecules for autoimmune conditions like atopic dermatitis, asthma, and inflammatory bowel disease. The lead candidate, a PKM2 inhibitor called SYX-5219, is already in phase 1 testing.

Boehringer also picked up two creative B-cell depletion programs in 2025: one that tricks the immune system into thinking rogue B cells are virus-infected (from Cue Biopharma), and another that uses a trispecific antibody to redirect T cells against those B cells (from CDR-Life). On top of that, the company has a TREM-1 blocker called BI 3032950 in phase 2 for ulcerative colitis. Killing one early-stage dud doesn't change that trajectory.

Amgen's inflammation portfolio still has serious firepower, too. TEZSPIRE, their asthma biologic, hit $1.5 billion in sales last year, growing 52% year over year. It recently picked up an FDA approval for chronic rhinosinusitis with nasal polyps and has a phase 3 trial running in eosinophilic esophagitis, with phase 3 trials planned in COPD. Otezla, their oral psoriasis pill, brought in $2.3 billion in 2025. And UPLIZNA grabbed two new FDA approvals last year in rare autoimmune conditions.

Losing rocatinlimab stings, but Amgen isn't exactly short on options.

Portfolio Discipline Is the New Flex

A few years ago, killing pipeline programs was seen as a sign of weakness. Wall Street would punish you. Investors would panic. Today, the narrative has flipped. In an era where drug development costs routinely exceed $2 billion per approved therapy and timelines stretch past a decade, knowing when to quit has become a competitive advantage.

Amgen is betting big on obesity (their MariTide program) and targeting $37 to $38.4 billion in total 2026 revenue. Boehringer posted 7.3% sales growth in 2025 and projects more momentum ahead. Both companies can afford to cut programs that aren't working because they have enough winners elsewhere to absorb the loss.

The lesson for the rest of the industry is sobering. If Boehringer and Amgen, with their resources and expertise, can't always get immunology right, smaller biotechs chasing the same targets face even longer odds. The cost of entry keeps climbing. The standard of care keeps improving. And the window for "good enough" drugs keeps shrinking.

Spring cleaning season in immunology is here. Don't be surprised if more programs end up in the bin before summer.

Two Biotechs Just Rang the IPO Bell on the Same Day

Seaport Therapeutics and Hemab Therapeutics both filed $100 million IPOs on the exact same day, targeting depression and rare bleeding disorders respectively. Their simultaneous filings say a lot about where the biotech IPO market stands in Q2 2026.